Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity

Experimental Neurology

Volumn 188, Issue 2, 2004, Pages 292-299

  Boehmer, L N ^a,b   Wu, M F ^b   John, J ^a,b   Siegel, J M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Research Service (151A3)   (United States)

Author keywords

Canine; Cataplexy; Dog; Genetic disorder; Hypocretin; Immunosuppression; Narcolepsy; Orexin; REM; Sleep

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE;

ACTIMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATAPLEXY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MALE; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; SLEEP PATTERN;

AGE OF ONSET; ANIMALS; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; FEMALE; GLUCOCORTICOIDS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; METHYLPREDNISOLONE; NARCOLEPSY; NUCLEIC ACID SYNTHESIS INHIBITORS; SEVERITY OF ILLNESS INDEX; SLEEP; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042792719     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.04.006     Document Type: Article

References (47)

1. Aldrich M.S. Diagnostic aspects of narcolepsy. Neurology. 50:1998;S2-S7
2. Bakker J.M., van Bel F., Heijnen C.J. Neonatal glucocorticoids and the developing brain: short-term treatment with life-long consequences? Trends Neurosci. 24:2001;649-653
3. Barnhill R.L., McDougall A.C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J. Am. Acad. Dermatol. 7:1982;317-323. (JID - 7907132)
4. Bian X., Seidler F.J., Slotkin T.A. Fetal dexamethasone exposure interferes with establishment of cardiac noradrenergic innervation and sympathetic activity. Teratology. 47:1993;109-117
5. Bounous D. Hematology of normal dogs and cats and responses to disease. Hoskins J. Veterinary Pediatrics: Dogs and Cats from Birth to Six Months. 1995;337-353 W.B. Saunders, Philadelphia
6. Cohen S. Sleep regulation with thalidomide. Am. J. Psychiatry. 116:1960;1030-1031. (JID - 0370512)
7. Douglass A.B., Harris L., Pazderka F. Monozygotic twins concordant for the narcoleptic syndrome. Neurology. 39:1989;140-141
8. Fredrikson M., Hursti T.J., Steineck G., Furst C.J., Borjesson S., Peterson C. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br. J. Cancer. 70:1994;642-645
9. Goldman L., Bennett J. Cecil Textbook of Medicine. 2000;W.B. Saunders, Philadelphia
10. Gulyani S., Wu M.-F., Nienhuis R., John J., Siegel J.M. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Neuroscience. 112:2002;355-365
11. Honda Y., Doi Y., Juji T., Satake M. Narcolepsy and HLA: positive DR2 as a prerequisite for the development of narcolepsy. Folia Psychiatr. Neurol. Jpn. 38:1984;360
12. Ichinose M., Asai M., Sawada M., Sasaki K., Oomura Y. Induction of outward current by orexin-B in mouse peritoneal macrophages. FEBS Lett. 440:1998;51-54
13. Ito M., Blumberg B.M., Mock D.J., Goodman A.D., Moser A.B., Moser H.W., Smith K.D., Powers J.M. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J. Neuropathol. Exp. Neurol. 60(10):2001;1004-1019. (Oct.)
14. John J., Wu M.F., Maidment N.T., Siegel J.M. Developmental changes in hypocretin-1 (orexin-A) level in canine narcolepsy. Soc. Neurosci. Abstr. 27:2001;8.2
15. Johnston M.V., Silverstein F.S., Greenberg H., Knutsen C.A., Chandler W., Phillips T., Ensminger W.D. Effects of intraventricular methotrexate on cerebrospinal fluid monoamine metabolites in rhesus monkeys. Cancer Treat. Rep. 70:1986;1205-1209
16. Kanbayashi T., Nishino S., Hishikawa Y., Dement W.C., Mignot E. Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. Neuroreport. 12:1996;1881-1886. (GENERIC) Ref Type: Journal (Full)
17. Kilduff T.S., Radde L., Burtch M., Steinman L., Dement W.C. Immunosuppression with cyclosporine as a treatment for canine narcolepsy. Sleep Res. 16:1987;369
18. Lin L., Faraco J., Kadotani H., Rogers W., Lin X., Qui X., de Jong P., Nishino S., Mignot E. The REM sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor gene. Cell. 98:1999;365-376
19. Matthews S.J., McCoy C. Thalidomide: a review of approved and investigational uses. Clin. Ther. 25:2003;342-395. (JID - 7706726)
20. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;S16-S22
21. Mignot E., Guilleminault C., Dement W.C., Grumet C. Genetically determined animal models of narcolepsy, a disorder of REM sleep. Driscoll D. Genetically Determined Animal Models of Neurobehavioral Dysfunction. 1992;554-557 Birkhauser Boston, Cambridge
22. Mignot E., Renaud A., Nishino S., Arrigoni J., Guilleminault C., Dement W.C. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl.). 113:1993;76-82
23. Mitler M.M. Toward an animal model of narcolepsy-cataplexy. Guilleminault C., Dement W.C., Passouant P. Narcolepsy. 1976;387-409 Spectrum Publications, New York
24. Montplaisir J., Poirier G. Narcolepsy in monozygotic twins. Neurology. 37:1987;1089-1092
25. Montplaisir J., Poirier G. HLA in narcolepsy in Canada. Honda Y., Juji T. HLA in Narcolepsy. 1988;97-107 Springer-Verlag, Berlin
26. Nambu T., Sakurai T., Mizukami K., Hosoya Y., Yanagisawa M., Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res. 827:1999;243-260
27. Partinen M., Hublin C., Kaprio J., Koskenvuo M., Guilleminault C. Twin studies in narcolepsy. Sleep. 17:1994;S13-S16
28. Peyron C., Tighe D.K., van den Pol A.N., De Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18:1998;9996-10015
29. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M., Pedrazzoli M., Padigaru M., Kucherlapati M., Fan J., Maki R., Lammers G.J., Bouras C., Kucherlapati R., Nishino S., Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6:2000;991-997
30. Pollmacher T., Schulz H., Geisler P., Kiss E., Albert E.D., Schwarzfischer F. DR-2-positive monozygotic twins discordant for narcolepsy. Sleep. 13:1990;336-343
31. Riehl J., Nishino S., Cederberg R., Dement W.C., Mignot E. Development of cataplexy in genetically narcoleptic dobermans. Exp. Neurol. 152:1998;292-302
32. Roitt I., Brostoff J., Male D. Immunology. 2003;Mosby, New York
33. Scammell T.E. The neurobiology, diagnosis, and treatment of narcolepsy. Ann. Neurol. 53:2003;154-166
34. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins). Cell. 98:1999;409-412
35. Siegel J.M., Nienhuis R., Fahringer H., Paul R., Shiromani P., Dement W.C., Mignot E., Chiu C. Neuronal activity in narcolepsy: identification of cataplexy related cells in the medial medulla. Science. 262:1991;1315-1318
36. Siegel J.M., Nienhuis R., Fahringer H., Gulyani S., Mignot E., Switzer R.C. Evidence for localized neuronal degeneration in the narcoleptic dog. Soc. Neurosci. Abstr. 21:1995;1235
37. Siegel J.M., Nienhuis R., Gulyani S., Ouyang S., Wu M.F., Mignot E., Switzer R.C., Cornford M. Neuronal degeneration in canine narcolepsy. J. Neurosci. 19:1999;248-257
38. Silverstein F.S., Johnston M.V. A model of methotrexate encephalopathy: neurotransmitter and pathologic abnormalities. J. Child Neurol. 1:1986;351-357
39. Silverstein F.S., Hutchinson R.J., Johnston M.V. Cerebrospinal fluid biogenic amine metabolites in children during treatment for acute lymphocytic leukemia. Pediatr. Res. 20:1986;285-291
40. Spencer M.J., Tidball J.G. Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul. Disord. 11(6-7):2001;556-564. (Sept.)
41. Steiger A. Sleep and the hypothalamo-pituitary-adrenocortical system. Sleep Med. Rev. 6(2):2002;125-138. (Apr.)
42. Tafti M., Nishino S., Aldrich M.S., Liao W., Dement W.C., Mignot E. Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model. J. Neurosci. 16:1996;4588-4595
43. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 27:2000;469-474
44. Thannickal T.C., Nienhuis R., Ramanathan L., Gulyani S., Turner K., Chestnut B., Siegel J.M. Preservation of hypocretin neurons in genetically narcoleptic dogs. Sleep. 23:2000;A296
45. Wu M.F., Gulyani S., Yao E., Mignot E., Phan B., Siegel J.M. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience. 91:1999;1389-1399
46. Wu M.F., John J., Maidment N., Lam H.A., Siegel J.M. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283(5):2002;R1079-R1086. (Nov.)
47. Yuwiler A., Simon M., Bennett B., Plotkin S., Wallace R., Brammer G., Ulrich R. Effect of neonatal corticoid treatment on tryptophan and serotonin metabolism. Endocrinol. Exp. 12:1978;21-31